Azizul Haque to Encephalomyelitis, Autoimmune, Experimental
This is a "connection" page, showing publications Azizul Haque has written about Encephalomyelitis, Autoimmune, Experimental.
Connection Strength
0.706
-
A Novel Aza-MBP Altered Peptide Ligand for the Treatment of Experimental Autoimmune Encephalomyelitis. Mol Neurobiol. 2018 01; 55(1):267-275.
Score: 0.138
-
Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment. J Neuroimmunol. 2017 02 15; 303:22-30.
Score: 0.129
-
Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. J Neurochem. 2014 Jul; 130(2):268-79.
Score: 0.105
-
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and ROR?t responses and by increasing IL-10 production in experimental allergic encephalomyelitis. J Neuroimmunol. 2013 Jan 15; 254(1-2):117-24.
Score: 0.097
-
Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol. 2011 Mar; 232(1-2):136-44.
Score: 0.084
-
Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 Feb 26; 219(1-2):47-53.
Score: 0.080
-
Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008 Nov 15; 204(1-2):58-65.
Score: 0.073